Table 4.

Details of last bortezomib-containing therapy [(regimen, duration, best treatment response, relapsed and bortezomib-refractory per IMWG criteria, primary bortezomib-refractory per IMWG criteria, time to next treatment (TNT), time between last and current bortezomib-containing regimen (months), treatment regimens and respective response between last and current bortezomib-containing regimen)], in conjunction with details of the current bortezomib+nelfinavir therapy [(best response, total number of bortezomib+nelfinavir cycles administered during trial and during subsequent off label therapy, time to next treatment (TNT)] for the 6 MM patients treated in the extension cohort of the trial.